HealthCare Global Enterprises Venda descoberta % de circulação
Qual é o Venda descoberta % de circulação de HealthCare Global Enterprises?
O Venda descoberta % de circulação de HealthCare Global Enterprises Limited é N/A
Qual é a definição de Venda descoberta % de circulação?
Porcentagem de venda de ações descobertas em circulação é a quantidade de ações que estão sendo vendidas descobertas comparada com a circulação de ações totais, expressa como uma porcentagem.
Short percentage of float, or short interest ratio, is calculated by taking the total amount of shares shorted and dividing it by the total amount of shares available for trade. It is an indirect metric of investor sentiment. When short percentage of float is high, above 40%, it implies company investors hope shares will decline in value. The percentage is used by both fundamental and technical traders to identify trends. The short percentage of float can also be calculated for entire exchanges to determine the sentiment of the market as a whole. If it is high of around five or greater for an exchange, this can be taken as a bearish signal, and vice versa.
O que HealthCare Global Enterprises faz?
HealthCare Global Enterprises Limited, together with its subsidiaries, provides healthcare services focusing on cancer and fertility. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertility treatment services, as well as reproductive medicine services, including assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. It also operates four multi-specialty hospitals, including three under the HCG brand in Ahmedabad, Bhavnagar, and Rajkot in the state of Gujarat, as well as one under operations and management contract in Hubli in the state of Karnataka that primarily provide cardiology, neurology, orthopedics, gastroenterology, urology, internal medicine, and pulmonary and critical care. In addition, the company offers medical diagnostic services, including scientific testing and consultancy services in the pharmaceutical and medical sector. As of March 31, 2022, the company operated 22 comprehensive cancer centers, including 1 center in Africa. The company was founded in 1989 and is based in Bengaluru, India.